Open AccessSmoldering type adult T‐cell leukemia/lymphoma effectively treated with mogamulizumab (anti‐CC chemokine receptor 4 monoclonal antibody)—A case report
Author(s) -
Nishikawa Yotaro,
Mochida Kosuke,
Kubo Tamaki,
Horikawa Nagako,
Nemoto Rieko,
Amano Masahiro
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2155
Subject(s) - medicine , monoclonal antibody , lymphoma , hematopoietic stem cell transplantation , adult t cell leukemia/lymphoma , leukemia , monoclonal , immunology , antibody , disease , pathology , t cell leukemia
Key Clinical Message The use of mogamulizumab needs careful consideration because of severe adverse reactions such as graft‐vs‐host disease. However, refractory specific skin lesions of smoldering type adult T‐cell leukemia/lymphoma can be effectively treated with mogamulizumab when patients have no opportunity to receive hematopoietic stem cell transplantation like our case.